INFI News and Press, Infinity Pharmaceuticals Inc. From 07/27/21

- New clinical data from MARIO-275 and MARIO-3 suggest that the addition of eganelisib to standard of care regimens provides patient benefit - - Increases seen in overall survival in 2L urothelial cancer (UC) and in progression free survival in 1L triple negative breast cancer...

– MARIO-3 Phase 2 study evaluating eganelisib added to standard of care Tecentriq ® and Abraxane ® regimen in frontline triple negative breast cancer (TNBC)– – MARIO-275 Phase 2 study evaluating the addition of eganelisib to stand...

Marcelo Ricardo Daros/iStock via Getty Images B. Riley Securities has initiated the coverage of Infinity Pharmaceuticals ([[INFI]] -2.6%) with a buy rating highlighting the potential of the company’s immune-oncology candidate eganelisib (IPI-549), which is currently undergoing multiple...

Infinity Pharmaceuticals, Inc . (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, to...

The following slide deck was published by Infinity Pharmaceuticals, Inc. in conjunction with this event. For further details see: Infinity Pharmaceuticals (INFI) Investor Presentation - Slideshow

Infinity Pharmaceuticals, Inc. (INFI) Q1 2021 Earnings Conference Call May 13, 2021 4:30 PM ET Company Participants Jayne Kauffman – Senior Executive Coordinator Adelene Perkins – Chief Executive Officer Brian Schwartz – Consulting Chief Physician Larry Bloch – Pre...

–Updated TNBC data from MARIO-3 to be reported mid-year and 4Q’21– –Update for eganelisib in PD-L1 low, 2L advanced UC patients expected mid-year– –$92M public offering strengthens balance sheet for continued development of ega...

Infinity Pharmaceuticals, Inc . (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that addresses a fundamental biologic mechanism of immune suppression in cancer, wil...

Infinity Pharmaceuticals, Inc . (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that addresses a fundamental biologic mechanism of immune suppression in cancer, tod...

Infinity Pharmaceuticals, Inc . (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, to...